Quick Answer
Decoy Therapeutics Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2022.
Decoy Therapeutics Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2022 | $0.00 | -100.0% |
| 2021 | $1.84M | -64.8% |
| 2020 | $5.23M | +51.0% |
| 2019 | $3.47M | +77.6% |
| 2018 | $1.95M | +53.1% |
| 2017 | $1.27M | +26.1% |
| 2016 | $1.01M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| March 31, 2023 | $0.00 | — | — |
| September 30, 2022 | $0.00 | — | — |
| June 30, 2022 | $0.00 | -100.0% | — |
| March 31, 2022 | $0.00 | -100.0% | — |
| September 30, 2021 | $0.00 | -100.0% | -100.0% |
| June 30, 2021 | $571.4K | -54.0% | -55.0% |
| March 31, 2021 | $1.27M | +12.0% | -7.9% |
| September 30, 2020 | $1.38M | +57.5% | +10.9% |
- Decoy Therapeutics Inc. showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2022 period, Decoy Therapeutics Inc.’s revenue (asc 606) has declined by 100.0% (from $1.01 million to $0.00).
- The most recent figure is from Decoy Therapeutics Inc.’s fiscal year 2022 report (Form 10-K), filed with the SEC on March 27, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: